New Phase II Data Bolster vTv Therapeutics’ Glucokinase Activator Aspirations

Could Product Succeed Where SGLT2 Inhibitors Failed?

 
• By Alexandra Shimmings

The future for glucokinase activation is looking brighter after fresh data on vTv’s oral adjunct to insulin therapy in type 1 diabetes.

liver
Liver selectivity key for glucokinase activators? • Source: Shutterstock

More from Clinical Trials

More from R&D